Baiyunshan subsidiary's Ceftazidime injection gets consistency evaluation approval

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced that its controlled subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Tianxin Pharmaceutical), has received approval from the National Medical Products Administration for its Ceftazidime Injection (0.5g, 1.0g) to pass the generic drug quality and efficacy consistency evaluation. Tianxin Pharmaceutical submitted the application in December 2023.

Ceftazidime Injection is a third-generation cephalosporin antibiotic used for severe systemic infections, lower respiratory tract infections, and urinary tract infections. In 2024, total sales of Ceftazidime Injection in urban, county-level public hospitals, and online pharmacies in China amounted to RMB 185,877 million. Tianxin Pharmaceutical's sales of Ceftazidime Injection (0.5g, 1.0g) reached RMB 1,431.78 million in 2024.

As of the announcement date, Tianxin Pharmaceutical has invested approximately RMB 1,036 million (unaudited) in research and development for the Ceftazidime Injection consistency evaluation project. This approval is expected to boost the product's market competitiveness.